📊 Industry Moves
Whoop hiring former FDA digital-health committee chair Ami Bhatt signals that its screenless tracker wants to be taken seriously as a medical-grade health platform, not just a recovery-score machine. For consumers, that could mean more credible insights, but only if Whoop turns the hire into validated features rather than better-sounding marketing.
Marty’s Take:
Whoop’s next competitive advantage won’t be another recovery metric; it will be clinical credibility. Expect rivals to recruit medical leaders, pursue regulatory-grade validation, and reposition wearables as early-warning tools over the next year. That raises the bar for every buyer: compare evidence and actionable features, not credentials, when choosing the best fitness tracker.
Shop mentioned gear: Whoop
Source: Bloomberg
Related Reviews
